National Women’s Health Week

Medicines360 joins individuals and communities across the country in celebration of National Women’s Health Week, the annual weeklong observance led by the U.S. Department of Health and Human Services’ Office on Women’s Health (OWH). This year’s observance, perhaps more so than any in recent history, offers the nation a timely opportunity to center women and consider the myriad ways in which we should support all women achieving their best possible health outcomes.

The global pandemic has laid bare the inequities that women face in their lives. Just last month, Oxfam International published a report that women lost at least $800 billion in income last year, more than the equivalent of 98 countries’ gross domestic product combined1. In the U.S. alone, of the nearly ten million jobs lost since February 2020, women’s job losses accounted for 55%, with 100% of the jobs lost in December 2020 being jobs lost by women2.  Health equity will remain out of reach until we prioritize addressing the systemic barriers that prevent women from accessing the quality care and medicines they need.

At Medicines360, we recognize the essential role that equitable access to quality medicines plays in women’s health.  That is why we are committed to partnering with an array of stakeholders, including industry, healthcare providers, patients, and the government to support meaningful and positive change. We applaud the Biden administration for the strides it has taken to improve equitable access. From this week’s appointment of a well-regarded family planning expert to lead the nation’s family planning program to its efforts to develop and implement comprehensive strategic plans that incorporate women’s health as a central component of the public health agenda, the Biden administration is taking the much-needed action that supports both near-term and long-term public health goals.

There is still work to be done: improved diversity of women in clinical trials, increased transparency around women’s health scientific data and evidence, and increased investment in and innovation of women’s health products and services to name just a few.  Making progress in these areas coupled with a focus on access and affordability would significantly benefit women and their families.

During this National Women’s Health Week, let us all reflect on not only the women’s health challenges and successes of the past, but how we can continue efforts to eliminate inequities within existing healthcare systems. Doing so together, we can make an essential difference in the lives of women, everywhere.

  1. https://www.oxfam.org/en/press-releases/covid-19-cost-women-globally-over-800-billion-lost-income-one-year
  2. https://nwlc.org/wp-content/uploads/2021/01/December-Jobs-Day.pdf

About Medicines360

Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical organization with a mission to catalyze equitable access to medicines and devices through product development, policy advocacy, and collaboration with global and US partners. Medicines360, through its subsidiary Impact RH360, launched the Avibela Project to expand access to hormonal IUDs in low- and middle-income countries. For more information, visit medicines360.org

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.